New study tracks muscle decline in rare muscular dystrophy
NCT ID NCT06390566
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 25 people with limb-girdle muscular dystrophy type 2A (LGMD2A), a rare genetic disease that causes progressive muscle weakness. Researchers will measure how muscle strength changes over time and how it affects quality of life. The goal is to better understand the disease's natural course, which could help design future treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIMB GIRDLE MUSCULAR DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Henri Mondor
Créteil, Île-de-France Region, 94130, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can MRI scans reveal how ANO5 muscle disease progresses?
- Can MRI scans reveal the hidden pattern of muscle damage in a rare muscular dystrophy?
- Virtual group therapy aims to boost social skills in kids with rare muscle disease
- Paving the way: new study aims to sharpen tools for LGMD R1 trials
- One-Time gene therapy aims to halt rare muscle disease
- Experimental gene therapy targets rare muscle disease in first human test